retatrutide fat loss trial 🚨 BREAKING: Shows “Bariatric-Level” Weight in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide: 24% Weight Loss Without

Effective Weight Loss: Preliminary data suggests it may provide significant weight loss benefits, possibly surpassing other medications

This is better than what you get with other weight loss medicines right now

Tried cutting calories, subjecting yourself to endless workouts and diet trends, only to see the scale barely budge

Many countries allow personal importation of prescription medicines under specific conditions - especially when treatment is difficult to afford locally

Here is a summary of the data for Alabama: Medicaid spending on GLP-1s (past 12 months): $43,100,970 Medicaid spending on GLP-1s (YoY change): +107% Medicaid spending on GLP-1s per enrollee (past 12 months): $55 Total Medicaid enrollment: 787,325 Wegovy coverage (obesity-indicated): Yes Zepbound coverage (obesity-indicated): No Saxenda coverage (obesity-indicated): No Ozempic coverage (Type 2 diabetes-indicated): Yes Mounjaro coverage (Type 2 diabetes-indicated): Yes Rybelsus coverage (Type 2 diabetes-indicated): Yes For reference, here are the statistics for the entire United States: Medicaid spending on GLP-1s (past 12 months): $3,452,602,033 Medicaid spending on GLP-1s (YoY change): +142% Medicaid spending on GLP-1s per enrollee (past 12 months): $48 Total Medicaid enrollment: 72,429,055 Wegovy coverage (obesity-indicated): 34 states Zepbound coverage (obesity-indicated): 16 states Saxenda coverage (obesity-indicated): 19 states Ozempic coverage (Type 2 diabetes-indicated): 51 states* Mounjaro coverage (Type 2 diabetes-indicated): 46 states* Rybelsus coverage (Type 2 diabetes-indicated): 46 states *Including District of Columbia For more information, a detailed methodology, and complete results, see Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending

If pharmacy staff are suspected of circumventing MO HealthNet policy by altering diagnosis codes provided by the prescriber, such claims may be subject to audit and could lead to administrative action, including, but not limited to, claim recoupment